These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

123 related articles for article (PubMed ID: 7540012)

  • 1. Thyrotropin-releasing hormone in treatment of intractable epilepsy: neurochemical analysis of CSF monoamine metabolites.
    Takeuchi Y; Tominaga M; Mitsufuji N; Yamazoe I; Kawase S; Nishimura A; Matsuo S; Sawada T
    Pediatr Neurol; 1995 Feb; 12(2):139-45. PubMed ID: 7540012
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TRH increases cerebrospinal fluid concentration of kynurenine.
    Takeuchi Y; Matsushita H; Kawano H; Sakai H; Yoshimoto K; Sawada T
    Neuroreport; 1999 Nov; 10(17):3601-3. PubMed ID: 10619651
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Thyrotropin-releasing hormone: role in the treatment of West syndrome and related epileptic encephalopathies.
    Takeuchi Y; Takano T; Abe J; Takikita S; Ohno M
    Brain Dev; 2001 Nov; 23(7):662-7. PubMed ID: 11701274
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in CSF neurotransmitters in infantile spasms.
    Langlais PJ; Wardlow ML; Yamamoto H
    Pediatr Neurol; 1991; 7(6):440-5. PubMed ID: 1724602
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thyrotropin-releasing hormone in the treatment of intractable epilepsy.
    Kubek MJ; Garg BP
    Pediatr Neurol; 2002 Jan; 26(1):9-17. PubMed ID: 11814729
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A pilot study on the anticonvulsive effects of a thyrotropin-releasing hormone analog in intractable epilepsy.
    Matsuishi T; Yano E; Inanaga K; Terasawa K; Ishihara O; Shiotsuki Y; Katafuchi Y; Aoki N; Yamashita F
    Brain Dev; 1983; 5(4):421-8. PubMed ID: 6416101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effects of thyrotropin-releasing hormone for severe epilepsy in childhood: a comparative study with ACTH therapy.
    Matsumoto A; Kumagai T; Takeuchi T; Miyazaki S; Watanabe K
    Epilepsia; 1987; 28(1):49-55. PubMed ID: 3024959
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoamine metabolites in the CSF of epileptic patients.
    Laxer KD; Sourkes TL; Fang TY; Young SN; Gauthier SG; Missala K
    Neurology; 1979 Aug; 29(8):1157-61. PubMed ID: 37460
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Amine metabolites in cerebrospinal fluids and thyrotropin releasing hormone in spinocerebellar degeneration].
    Arai M
    Rinsho Shinkeigaku; 1988 Jun; 28(6):595-604. PubMed ID: 2466598
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination treatment of high-dose pyridoxal phosphate and low-dose ACTH in children with West syndrome and related disorders.
    Seki T
    Jpn J Psychiatry Neurol; 1990 Jun; 44(2):219-37. PubMed ID: 1701836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Biological aspects of suicide].
    Linkowski P; Mendlewicz J
    Acta Psychiatr Belg; 1983; 83(1):7-12. PubMed ID: 6193681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pituitary thyrotropin response to thyrotropin-releasing hormone in affective illness: relationship to spinal fluid amine metabolites.
    Gold PW; Goodwin FK; Wehr T; Rebar R
    Am J Psychiatry; 1977 Sep; 134(9):1028-31. PubMed ID: 409301
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of thyrotropin-releasing hormone in the treatment of cerebellar ataxia.
    Takeuchi Y; Fujiwara K; Ishimura K; Shimada Y; Ochi M; Yoshioka H; Sawada T
    Pediatr Neurol; 1989; 5(2):107-10. PubMed ID: 2469426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoamine neurotransmitters in early epileptic encephalopathies: New insights into pathophysiology and therapy.
    Juliá-Palacios N; Molina-Anguita C; Sigatulina Bondarenko M; Cortès-Saladelafont E; Aparicio J; Cuadras D; Horvath G; Fons C; Artuch R; García-Cazorla À;
    Dev Med Child Neurol; 2022 Jul; 64(7):915-923. PubMed ID: 35833444
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Adrenocorticotropic hormone versus pulsatile dexamethasone in the treatment of infantile epilepsy syndromes.
    Haberlandt E; Weger C; Sigl SB; Rauchenzauner M; Scholl-Bürgi S; Rostásy K; Karall D
    Pediatr Neurol; 2010 Jan; 42(1):21-7. PubMed ID: 20004858
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Elevated homovanillic acid in cerebrospinal fluid of children with infantile spasms.
    Ito M; Okuno T; Mikawa H; Osumi Y
    Epilepsia; 1980 Aug; 21(4):387-92. PubMed ID: 6156822
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neurotransmitter metabolites in medicated epileptic patients.
    Markianos M; Kalfakis N
    Funct Neurol; 1991; 6(4):367-70. PubMed ID: 1725777
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Substance P, thyrotropin-releasing hormone, and monoamine metabolites in cerebrospinal fluid in sleep apnea patients.
    Gislason T; Hedner J; Terenius L; Bisette G; Nemeroff CB
    Am Rev Respir Dis; 1992 Sep; 146(3):784-6. PubMed ID: 1381567
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Putative neurotransmitter abnormalities in infantile spasms: cerebrospinal fluid neurochemistry and drug effects.
    Pranzatelli MR
    J Child Neurol; 1994 Apr; 9(2):119-29. PubMed ID: 7911815
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors influencing effectiveness of thyrotropin-releasing hormone therapy for severe epilepsy in childhood: significance of serum prolactin levels.
    Matsumoto A; Kumagai T; Takeuchi T; Miyazaki S; Watanabe K
    Epilepsia; 1989; 30(1):45-9. PubMed ID: 2492223
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.